Filing Flows › Anika Therapeutics (ANIK) › Q2 2026 › vs Q1 2026
Anika Therapeutics (ANIK) Q2 2026 vs Q1 2026 (quarter over quarter)
Anika Therapeutics's revenue rose $3.0M (+10%) from $29.6M in Q1 2026 to $32.6M in Q2 2026. The biggest changes: OEM Channel +$1.7M (+10%); Commercial Channel +$1.3M (+11%). Gross margin 65.1% against 64.2% (+1.0 pts).
Anika Therapeutics, Q2 2026: revenue $32.6M (+16% year over year), operating margin 9.1%, net earnings $3.3M, operating cash flow −$684K. The chart draws each line against Q1 2026, the increases inside each band.
Margins
| Q2 2026 | Q1 2026 | Change | |
|---|---|---|---|
| Gross margin | 65.1% | 64.2% | +1.0 pts |
| Operating margin | 9.1% | -18.5% | +27.6 pts |
| Net margin | 10.1% | -17.1% | +27.2 pts |
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| OEM Channel | $18.7M | $17.0M | $1.7M | +10% |
| Commercial Channel | $13.9M | $12.6M | $1.3M | +11% |
| Revenue | $32.6M | $29.6M | $3.0M | +10% |
| Gross profit | $21.2M | $19.0M | $2.2M | +12% |
| Cost of revenue | $11.4M | $10.6M | $751K | +7% |
| Other income, net | $426K | $667K | −$241K | -36% |
| Operating profit | $3.0M | −$5.5M | $8.4M | — |
| Operating expenses | $18.3M | $24.5M | −$6.2M | -25% |
| Pre-tax earnings | $3.4M | −$4.8M | $8.2M | — |
| Research & development | $7.3M | $6.7M | $628K | +9% |
| SG&A | $10.9M | $17.8M | −$6.8M | -38% |
| Net earnings | $3.3M | −$5.1M | $8.4M | — |
| Income tax | $71K | $235K | −$164K | -70% |
| Operating cash sources | $7.3M | $7.8M | −$507K | -6% |
| Depreciation & amortization | $1.5M | $1.4M | $98K | +7% |
| Share-based compensation | $1.8M | $6.6M | −$4.8M | -72% |
| Cash used in operations | $684K | $4.8M | −$4.2M | -86% |
| Working capital & other | $7.3M | $7.8M | −$507K | -6% |
Questions
How much did Anika Therapeutics's revenue grow quarter over quarter in Q2 2026?
Anika Therapeutics's revenue rose $3.0M (+10%) from $29.6M in Q1 2026 to $32.6M in Q2 2026.
What drove Anika Therapeutics's revenue change in Q2 2026?
OEM Channel +$1.7M (+10%); Commercial Channel +$1.3M (+11%).